Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: DGX stock price vs WMT: inconclusive — current versus $357.08 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WMT's multiple
Implied fair value · at DGX's multiple
Needs DGX P/E.
Close Dec 31, 2025
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
14 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 95% equity / 5% debt · EV / Revenue 1.29x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Quest Diagnostics Inc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Walmart Inc. · implied price per share
Bear
$26.01
Base
$31.42
Bull
$38.87
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
DGX vs ABT
DANAHER CORP /DE/
DGX vs DHR
THERMO FISHER SCIENTIFIC INC.
DGX vs TMO
HCA Healthcare, Inc.
DGX vs HCA
LABCORP HOLDINGS INC.
DGX vs LH
WEST PHARMACEUTICAL SERVICES INC
DGX vs WST
TARGET CORP
DGX vs TGT
Costco Wholesale Corporation
DGX vs COST
Amazon.com, Inc.
DGX vs AMZN
CVS Health Corporation
DGX vs CVS
Walgreens Boots Alliance, Inc.
DGX vs WBA
DOLLAR GENERAL CORP
DGX vs DG
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe DGX can sustain its stronger margin profile while avoiding multiple compression from its higher leverage, then a cautious overweight or hold makes sense because DGX is cheaper than WMT on earnings and EBITDA but still trades above the top of the DCF range.
On a P/E basis, DGX at 27.3x trades at a discount to WMT at 40.8x, which would imply meaningful upside if DGX were rerated to WMT multiple. However, WMT-implied range is wide and the DCF range sits well below the current price, so the valuation signal is not one-directional.
Supporting Metrics
